Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132314 | 1.00 | HRH3 (0.45) | HRH3NPC1ALDH1A1TSHRRAB9A | |
| SCHEMBL6132231 | 1.00 | HRH3 (0.45) | HRH3NPC1ALDH1A1TSHRRAB9A | |
| SCHEMBL6132162 | 0.89 | HRH3 (0.52) | HRH3NPC1ALDH1A1TSHRRAB9A | |
| SCHEMBL6132237 | 0.89 | HRH3 (0.43) | HRH3NPC1ALDH1A1TSHRRAB9A | |
| SCHEMBL6132540 | 0.89 | HRH3 (0.43) | HRH3NPC1ALDH1A1TSHRRAB9A | |
| SCHEMBL6132240 | 0.89 | HRH3 (0.43) | HRH3NPC1ALDH1A1TSHRRAB9A | |
| SCHEMBL6135370 | 0.86 | USP2 (0.55) | HRH3NPC1RAB9ASMN1; SMN2CSNK2A2 | |
| SCHEMBL6135376 | 0.86 | USP2 (0.55) | HRH3NPC1RAB9ASMN1; SMN2CSNK2A2 | |
| SCHEMBL1743224 | 0.83 | HRH3 (0.50) | HRH3NPC1ALDH1A1RAB9A | |
| SCHEMBL6132186 | 0.81 | HDAC3 (0.44) | HRH3NPC1ALDH1A1TSHRRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884774-B2 | Cyclic hexapeptide derivatives | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-04-26 | — | — | US | disclosed |
| EP-1259535-B1 | CYCLIC HEXAPEPTIDE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-04-13 | — | — | EP | disclosed |
| US-20030083238-A1 | Cyclic hexapeptide derivatives | ASTELLAS PHARMA INC. (JP) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083238-A1 | Cyclic hexapeptide derivatives | NGLY1, ALG1, CHIT1 | HRH3 2597/4885NPC1 2414/4885ALDH1A1 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.